Online citations, reference lists, and bibliographies.
← Back to Search

The Microenvironmental Landscape Of Brain Tumors.

Daniela F. Quail, J. Joyce
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The brain tumor microenvironment (TME) is emerging as a critical regulator of cancer progression in primary and metastatic brain malignancies. The unique properties of this organ require a specific framework for designing TME-targeted interventions. Here, we discuss a number of these distinct features, including brain-resident cell types, the blood-brain barrier, and various aspects of the immune-suppressive environment. We also highlight recent advances in therapeutically targeting the brain TME in cancer. By developing a comprehensive understanding of the complex and interconnected microenvironmental landscape of brain malignancies we will greatly expand the range of therapeutic strategies available to target these deadly diseases.
This paper references
10.1073/pnas.1525528113
New tools for studying microglia in the mouse and human CNS
Mariko L. Bennett (2016)
tases from metastatic breast cancer patients: a prospective study
P. Mulvenna (2016)
10.1007/s004010051093
Neutrophil infiltration into human gliomas
G. Fossati (1999)
10.1038/nrc.2016.2
Acquired resistance to immunotherapy and future challenges
N. Restifo (2016)
10.1016/j.cell.2010.03.014
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian (2010)
10.1126/SCIENCE.1095505
Endothelial Cells Stimulate Self-Renewal and Expand Neurogenesis of Neural Stem Cells
Q. Shen (2004)
10.3389/fncel.2014.00362
The impact of microglial activation on blood-brain barrier in brain diseases
A. D. da Fonseca (2014)
10.1046/j.1469-7580.2002.00065.x
Blood–brain barrier breakdown in septic encephalopathy and brain tumours *
D. Davies (2002)
10.1038/nrc3546
Endothelin 1 in cancer: biological implications and therapeutic opportunities
L. Rosanò (2013)
10.1093/neuonc/nov245
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
N. Butowski (2016)
10.1016/S1474-4422(15)00221-5
Implications of the discovery of brain lymphatic pathways
Jeffrey J Iliff (2015)
A survey of metastatic central nervous system tumors to cervical lymph nodes
A. Morikawa (2010)
10.1016/j.it.2015.08.006
Revisiting the Mechanisms of CNS Immune Privilege.
Antoine Louveau (2015)
10.1038/ni.3423
Origin, fate and dynamics of macrophages at central nervous system interfaces
T. Goldmann (2016)
10.3389/fonc.2016.00049
Systemic Immunotherapy for the Treatment of Brain Metastases
Justine V. Cohen (2016)
10.1002/jlb.56.6.732
Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen‐presenting cells
E. Ulvestad (1994)
10.1038/nrn2175
Angiogenesis in brain tumours
R. Jain (2007)
10.1016/S1556-0864(16)30311-2
Could neutrophil‐to‐lymphocyte ratio be predictor of brain metastases in non small cell lung cancer?: 203P
M. Serdarević (2016)
10.1038/nri3070
Monocyte recruitment during infection and inflammation
C. Shi (2011)
10.1016/S1470-2045(16)30053-5
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
S. Goldberg (2016)
10.1038/nature14336
Therapy-induced tumour secretomes promote resistance and tumour progression
A. Obenauf (2015)
10.1038/nrc3053
Brain metastases as preventive and therapeutic targets
P. Steeg (2011)
niche for brain tumor stem cells
P. Carmeliet (2011)
10.1038/onc.2012.313
Elevated PLGF contributes to small-cell lung cancer brain metastasis
B. Li (2013)
10.1016/j.ddtec.2016.07.008
Modulating the paracellular pathway at the blood-brain barrier: current and future approaches for drug delivery to the CNS.
Eoin O'Keeffe (2016)
10.1038/nature18268
Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer
Q. Chen (2016)
10.1016/j.bbamem.2008.10.022
The blood-brain barrier in brain homeostasis and neurological diseases.
N. Weiss (2009)
10.1002/path.2370
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Y. Komohara (2008)
10.1038/nri3391
Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates
R. Shechter (2013)
10.1158/1078-0432.CCR-16-1327
Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
M. Osswald (2016)
10.1016/j.celrep.2016.10.052
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies.
Robert L Bowman (2016)
10.1016/J.CCR.2004.10.011
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
F. Winkler (2004)
10.1080/14737140.2016.1229600
Immunological effects of chemotherapy and radiotherapy against brain tumors
T. Weiss (2016)
10.1158/1078-0432.CCR-06-0053
Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells
P. Fecci (2006)
10.14694/EDBK_100005
Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
A. Berghoff (2016)
Ipilimu - mab in patients with melanoma and brain metastases : an open - label , phase 2 trial
J. Massague (2012)
IL17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis
N. Engl (2015)
10.1016/bs.acr.2014.11.007
Glycosylation alterations in lung and brain cancer.
H. Lemjabbar-Alaoui (2015)
An in vivo immunotherapy screen of costimulatory molecules identifies FcOX 40 L as a potent reagent for the treatment of established murine gliomas
D. A. Mustafa (2012)
10.1093/neuonc/noq082
Glioma cancer stem cells induce immunosuppressive macrophages/microglia.
A. Wu (2010)
10.1158/1078-0432.CCR-13-1279
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
J. Liang (2013)
10.1038/ncb3090
Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth
W. Zhou (2015)
Cancer Cell Perspective Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
A. R. Bresnick (2015)
10.1189/jlb.0306176
T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa
J. Goldmann (2006)
10.1016/j.immuni.2016.12.012
Neutrophils in Homeostasis, Immunity, and Cancer.
J. A. Nicolás-Ávila (2017)
10.1002/PATH.1711590209
Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells
J. Lowe (1989)
Purinergic receptor P 2 RY 12-dependent microglial closure of the injured blood – brain barrier
N. Loua (2016)
10.2340/00015555-1654
Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
M. Konstantinou (2014)
10.1056/NEJMoa1308345
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
O. Chinot (2014)
10.1038/nature14282
IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
S. Coffelt (2015)
10.1038/srep38585
Baseline neutrophil–lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer
Y. W. Koh (2016)
10.1038/nature10144
Molecular mechanisms and clinical applications of angiogenesis
P. Carmeliet (2011)
10.1016/j.ccell.2016.06.021
Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils.
Y. Liu (2016)
10.1371/journal.pmed.1000010
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
James F Curtin (2009)
10.1038/nrc3893
S100 proteins in cancer
A. Bresnick (2015)
10.1038/nrneurol.2015.139
Prospects of immune checkpoint modulators in the treatment of glioblastoma
M. Preusser (2015)
T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
T. Pukrop (2010)
10.1016/S1470-2045(12)70090-6
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
K. Margolin (2012)
10.1158/0008-5472.CAN-09-0814
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
A. G. Sorensen (2009)
10.1093/neuonc/nos158
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Y. Piao (2012)
10.1038/srep23834
Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways
L. A. Bentolila (2016)
10.1016/j.ccell.2016.03.002
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.
T. Phoenix (2016)
10.1073/pnas.1424927112
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils
Amy-Jo Casbon (2015)
10.1016/j.cell.2016.10.039
Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth
B. Hu (2016)
10.1101/gad.1627008
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
D. Hambardzumyan (2008)
10.1172/jci.insight.85841
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.
Konrad R Gabrusiewicz (2016)
10.1200/JCO.2008.19.8721
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
H. Friedman (2009)
The biology of brain metastasestranslation to new therapies
AF Eichler (2011)
10.1016/j.stem.2010.01.001
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.
N. Charles (2010)
10.1002/glia.10147
Microglia in brain tumors
M. Gräber (2002)
Hetero - geneous bloodtumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer
N. Lou (2010)
10.1038/nature13989
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
Elisa Gomez Perdiguero (2015)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1158/0008-5472.CAN-05-3773
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
P. Fecci (2006)
Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.
P. Medawar (1948)
10.1038/nrclinonc.2011.58
The biology of brain metastases—translation to new therapies
A. Eichler (2011)
10.1200/JCO.2009.26.3988
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
T. Batchelor (2010)
10.1200/JCO.2016.66.6552
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
E. Bouffet (2016)
homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye
Y. A. Miroshnikova (2016)
10.1158/1078-0432.CCR-12-0990
An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Katherine A Murphy (2012)
10.1016/j.stem.2014.02.002
Metastatic stem cells: sources, niches, and vital pathways.
T. Oskarsson (2014)
10.1158/1078-0432.CCR-14-0832
Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
P. Fecci (2014)
10.1016/j.neuron.2014.02.040
Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain
Monica R. P. Elmore (2014)
10.1038/nrn3898
Astrocyte barriers to neurotoxic inflammation
M. Sofroniew (2015)
10.1038/nrclinonc.2016.56
Immunotherapy: Exploiting mismatch repair in GBM
L. Hutchinson (2016)
physiological angiogenesis and angiogenesis
J. M111.008466. Neman (2014)
human breast cancer and lung cancer brainmetastases inmice bymacitentan, a dual antagonist of endothelin receptors, combined with paclitaxel
W. P. Leenders (2004)
10.1523/JNEUROSCI.6221-11.2012
Genomic Analysis of Reactive Astrogliosis
Jennifer L Zamanian (2012)
10.1016/j.neuron.2013.12.034
Reactive Gliosis and the Multicellular Response to CNS Damage and Disease
J. E. Burda (2014)
The role of human gliomainfiltrating microglia/macrophages in mediating antitumor immune responses
SF Hussain (2006)
10.1016/J.CCR.2005.08.002
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
M. De Palma (2005)
10.1158/1078-0432.CCR-10-1564
Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
P. Lockman (2010)
rebral melanomametastases results in sustained tumor progression via vessel co-option
H. Lemjabbar-Alaoui (2015)
10.1101/gad.261982.115
Cancer stem cells in glioblastoma.
J. Lathia (2015)
10.1038/nm.3394
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail (2013)
approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
S. J. Coniglio (2012)
10.1038/nn.3597
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.
S. Sarkar (2014)
10.1016/j.ccr.2009.04.001
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
Y. Wang (2009)
10.1126/scitranslmed.aae0105
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma
Abhishek D Garg (2016)
10.1038/nature09557
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
L. Ricci‐Vitiani (2010)
10.1038/nature09734
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
L. Ricci‐Vitiani (2011)
10.1158/1078-0432.CCR-14-0861
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Lucia B. Jilaveanu (2014)
10.1016/j.stem.2014.01.005
Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth.
A. Pietras (2014)
10.2217/imt.14.48
Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma.
Robert L Bowman (2014)
untreated brain metastases: early analysis of a non-randomised, openlabel, phase 2 trial
J. Goldmann (2006)
10.1016/j.stem.2010.02.018
Integrin alpha 6 regulates glioblastoma stem cells.
J. Lathia (2010)
10.4049/jimmunol.0901352
Extracellular Matrix of Glioblastoma Inhibits Polarization and Transmigration of T Cells: The Role of Tenascin-C in Immune Suppression
Jyun-Yuan Huang (2010)
10.1093/neuonc/not031
Premetastatic soil and prevention of breast cancer brain metastasis.
Y. Liu (2013)
10.1016/j.biocel.2016.05.002
The extracellular matrix niche microenvironment of neural and cancer stem cells in the brain.
J. Reinhard (2016)
10.1158/1078-0432.CCR-15-1836
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
L. T. Lyle (2016)
10.1056/NEJMoa1610497
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
C. Brown (2016)
10.1016/j.lungcan.2016.05.031
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
E. Dudnik (2016)
survival but not overall survival in newly diagnosed glioblastoma
K. Margolin (2012)
10.1056/NEJMoa1500925
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
J. Buckner (2016)
10.1038/nrc.2016.52
Neutrophils in cancer: neutral no more
S. Coffelt (2016)
10.1038/ni.2419
Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages
E. Gautier (2012)
10.1158/1078-0432.CCR-10-2563
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
R. Prins (2010)
203P: Could neutrophil-tolymphocyte ratio be predictor of brain metastases in non small cell lung cancer
M Serdarevic (2016)
10.1038/nature16140
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
S. Wculek (2015)
10.1016/j.cell.2014.01.040
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
M. Valiente (2014)
10.1056/NEJMoa1308573
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
M. Gilbert (2014)
10.1126/SCIENCE.1104819
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
R. Jain (2005)
10.1002/eji.200839120
IL-17-producing gammadelta T cells.
R. O’Brien (2009)
10.3171/2016.8.JNS16899
Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis.
K. Mitsuya (2017)
10.1038/nn1657
Pigment epithelium–derived factor is a niche signal for neural stem cell renewal
C. Ramírez-Castillejo (2006)
10.1093/neuonc/nou141
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
A. Morikawa (2015)
10.1038/nature14432
Structural and functional features of central nervous system lymphatics
Antoine Louveau (2015)
10.1158/1078-0432.CCR-04-0823
Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option
W. Leenders (2004)
10.4161/cc.9.15.12710
The perivascular niche microenvironment in brain tumor progression
N. Charles (2010)
10.1038/nrn1824
Astrocyte–endothelial interactions at the blood–brain barrier
N. Abbott (2006)
10.1593/NEO.10602
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels.
Q. Lin (2010)
10.1038/nri3405
Molecular mechanisms of T cell co-stimulation and co-inhibition
L. Chen (2013)
10.1097/01.COT.0000289242.47980.F9
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
R. Stupp (2005)
10.1093/annonc/mdu465
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.
C. Levy (2014)
Serpins promote cancer
M Valiente
administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
C. Calabrese (2007)
10.1038/nrc3258
Cancer immunotherapy via dendritic cells
K. Palucka (2012)
10.1074/mcp.M111.008466
A Proteome Comparison Between Physiological Angiogenesis and Angiogenesis in Glioblastoma
D. Mustafa (2012)
10.1038/nri3265
The anatomical and cellular basis of immune surveillance in the central nervous system
R. Ransohoff (2012)
10.1038/ncb3011
Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S
L. Sevenich (2014)
10.1073/pnas.1520398113
Purinergic receptor P2RY12-dependent microglial closure of the injured blood–brain barrier
Nanhong Lou (2016)
10.1084/JEM.154.2.347
Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain
D. Hart (1981)
10.1126/science.aaa6204
T cell exclusion, immune privilege, and the tumor microenvironment
J. Joyce (2015)
10.1158/0008-5472.CAN-04-0074
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
R. Tong (2004)
10.1007/s11060-013-1164-9
The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme
R. Bambury (2013)
Purinergic receptor P2RY12dependent microglial closure of the injured blood-brain barrier
N Lou (2016)
10.1038/nm0901-987
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
R. Jain (2001)
10.1038/nm.3337
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
S. Pyonteck (2013)
IL17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis
N. Engl (2015)
10.18632/oncotarget.10898
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
A. Bertaut (2016)
10.1158/1078-0432.CCR-14-3195
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
S. Kim (2015)
10.1038/ni.3666
The movers and shapers in immune privilege of the CNS
B. Engelhardt (2017)
10.1038/nrn1326
Regeneration beyond the glial scar
J. Silver (2004)
10.1016/S1470-2045(13)70585-0
Clinical use of dendritic cells for cancer therapy.
S. Anguille (2014)
10.1093/neuonc/now037
Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
H. Lee (2016)
10.1111/febs.12109
Proteoglycans and their roles in brain cancer
A. Wade (2013)
10.1016/j.cell.2011.06.014
Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma
C. Liu (2011)
10.1007/s00405-010-1357-1
A survey of metastatic central nervous system tumors to cervical lymph nodes
Vanni Mondin (2010)
AntiPD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy
D. Mathios (2016)
10.1215/15228517-2006-008
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
S. Hussain (2006)
10.1007/s11060-014-1400-y
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
P. Queirolo (2014)
10.1093/neuonc/not082
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
C. Lu-Emerson (2013)
340 Cancer Cell 31 , March 13 , 2017 Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells
S. Robel (2010)
10.1007/S11725-015-0588-4
PD-1 blockade in tumors with mismatch-repair deficiency
T. Aparicio (2015)
10.1073/pnas.1322098111
Human breast cancer metastases to the brain display GABAergic properties in the neural niche
J. Neman (2014)
10.1200/JCO.2008.16.3055
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
T. Kreisl (2009)
mental brain metastases of breast cancer
T. Takano (2016)
pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme
T. T. Batchelor (2007)
Kinetics of vascular
F. Winkler (2004)
10.1038/nature02604
Cell fusion-independent differentiation of neural stem cells to the endothelial lineage
A. Wurmser (2004)
Glioblastoma after chimeric antigen receptor T-cell therapy
J. C. Buckner (2016)
10.1126/scitranslmed.aag2942
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios (2016)
10.1016/j.stem.2008.07.025
A specialized vascular niche for adult neural stem cells.
M. Tavazoie (2008)
10.1038/nrneurol.2014.47
Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma
Hemi Malkki (2014)
10.1158/1078-0432.CCR-06-2070
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
P. Fecci (2007)
10.1016/S0140-6736(16)30825-X
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
P. Mulvenna (2016)
10.1038/ni.3324
New insights into the multidimensional concept of macrophage ontogeny, activation and function
F. Ginhoux (2015)
10.1038/nature17038
Metastatic colonization by circulating tumour cells
J. Massagué (2016)
10.1084/jem.20142290
A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
Aleksanteri Aspelund (2015)
10.1080/19336918.2014.1000071
Role of tenascins in the ECM of gliomas
Nicole Brösicke (2015)
homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye
Y. A. Miroshnikova (2016)
10.1126/SCIENCE.3276004
Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo.
W. Hickey (1988)
10.1038/nature09624
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang (2010)
10.1007/s12032-015-0487-0
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes
W. Chen (2015)
10.1080/02688690120036775
Emerging molecular mechanisms of brain tumour oedema.
M. Papadopoulos (2001)
10.1128/CVI.00292-09
Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model
T. Kim (2009)
10.1038/ncb3429
Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression
Y. Miroshnikova (2016)
barrier in brain homeostasis and neurological diseases
T. Weiss (2016)
VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
J. Wei (2010)
10.1038/nrc2073
Candidate mechanisms for chemotherapy-induced cognitive changes
T. Ahles (2007)
10.1038/nrc2246
Making a tumour's bed: glioblastoma stem cells and the vascular niche
R. Gilbertson (2007)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1016/J.BREASTDIS.2014.07.037
Human breast cancer metastases to the brain display GABAergic properties in the neural niche
G. Shankar (2014)
10.1038/nn2014
Local self-renewal can sustain CNS microglia maintenance and function throughout adult life
B. Ajami (2007)
10.1126/science.1194637
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
F. Ginhoux (2010)
10.1158/1541-7786.MCR-16-0223
Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival
Soumi Kundu (2016)
10.1007/s10545-013-9608-0
Blood–brain barrier structure and function and the challenges for CNS drug delivery
N. Abbott (2013)
10.1007/s11060-014-1366-9
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression
M. McNamara (2014)
10.1038/nature15376
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
L. Zhang (2015)
10.2119/molmed.2011.00217
Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling
S. Coniglio (2012)
10.1038/nrn2978
The stem cell potential of glia: lessons from reactive gliosis
S. Robel (2011)
10.1158/1078-0432.CCR-15-0713
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
C. Pham (2015)
10.1002/glia.21022
Microglia promote colonization of brain tissue by breast cancer cells in a Wnt‐dependent way
T. Pukrop (2010)
10.1634/theoncologist.2009-0121
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
M. Cohen (2009)
10.1593/NEO.11112
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy.
S. J. Kim (2011)
10.1007/s00401-016-1620-7
Mutant IDH1 and thrombosis in gliomas
Dusten Unruh (2016)
10.1038/nature16071
Brain tumour cells interconnect to a functional and resistant network
M. Osswald (2015)
10.1038/nn.4185
The role of microglia and macrophages in glioma maintenance and progression
D. Hambardzumyan (2015)
administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
C. Calabrese (2007)
10.1016/J.CCR.2006.11.020
A perivascular niche for brain tumor stem cells.
C. Calabrese (2007)
10.1016/j.cell.2015.04.012
Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion
Humsa S. Venkatesh (2015)
10.1056/NEJMe1313309
Bevacizumab in glioblastoma--still much to learn.
H. Fine (2014)
10.1038/nature08021
Genes that mediate breast cancer metastasis to the brain
P. Bos (2009)
10.4049/jimmunol.179.2.845
Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells1
F. Masson (2007)
10.1038/nature14320
Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
D. Mitchell (2015)
10.1016/J.CCR.2006.11.021
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
T. Batchelor (2007)
10.1126/science.aad3018
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Daniela F. Quail (2016)



This paper is referenced by
10.1093/neuonc/nox169
Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.
Katrin Deumelandt (2018)
10.15252/emmm.201708431
Fighting vessel dysmorphia to improve glioma chemotherapy
Marja Lohela (2017)
10.1007/s00418-018-1631-7
Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma
G. Kazanskaya (2018)
10.1016/s0049-3848(20)30405-9
Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations.
N. Tawil (2020)
10.1007/s11910-020-01039-1
Advances in Management of Brain and Leptomeningeal Metastases
V. A. Venur (2020)
10.1038/s41388-018-0515-6
CD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2
T. Chen (2018)
10.1016/j.semcancer.2018.01.015
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
F. Passiglia (2018)
10.1016/j.aanat.2019.151440
Establishment of a glioblastoma in vitro (in)complete resection dual co-culture model suitable for drug testing.
C. Schmitt (2019)
10.1093/neuonc/noz080
Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.
Xiaofan Guo (2019)
10.3791/59384
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish.
Vadim Le Joncour (2019)
10.1016/j.canlet.2018.06.041
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Tianfu Yu (2018)
10.1007/978-3-030-37184-5_8
Oligodendrocyte Progenitor Cells in the Tumor Microenvironment.
T. Hide (2020)
10.1016/j.trecan.2018.01.003
The Evolving Landscape of Brain Metastasis.
M. Valiente (2018)
10.1097/WCO.0000000000000491
The promises of immunotherapy in gliomas
I. Mildenberger (2017)
10.3390/cancers12082122
Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions
Kha-Liang Lee (2020)
10.1007/978-3-030-23417-1_7
Preclinical Models of Brain Metastases
Alex Wu (2020)
10.1016/j.apsb.2020.08.010
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Y. Zhu (2020)
10.1007/s43152-020-00016-7
The Effect of Glioblastoma on Pericytes
M. L. Molina (2020)
10.1039/c9ra04590b
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
Min Zhang (2019)
10.3389/fphar.2019.01333
The Ancient Chinese Decoction Yu-Ping-Feng Suppresses Orthotopic Lewis Lung Cancer Tumor Growth Through Increasing M1 Macrophage Polarization and CD4+ T Cell Cytotoxicity
L. Wang (2019)
10.1038/s41388-019-0680-2
Isolation and characterization of patient-derived CNS metastasis-associated stromal cell lines
B. Y. Tew (2019)
10.1186/s12974-020-01753-0
Metastatic breast cancer cells induce altered microglial morphology and electrical excitability in vivo
A. Simon (2020)
10.1158/2159-8290.CD-19-1355
Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner.
Defne Bayik (2020)
10.1080/14712598.2020.1713085
Prospects of biological and synthetic pharmacotherapies for glioblastoma
David B Altshuler (2020)
10.1101/2020.07.16.206318
Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
L. Zhao (2020)
10.32598/irjns.5.2.51
Steroids use in glioblastoma: why do we persist?
Mostafa Fatehi Hassanabad (2019)
10.3390/mps3010011
A Simple and Reliable Protocol for the Preparation and Culturing of Fresh Surgically Resected Human Glioblastoma Tissue
Liyen Katrina Kan (2020)
10.3390/ijms20112810
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Wei X. Huff (2019)
10.1111/cns.13072
Integrated profiling identifies caveolae‐associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients
Q. Guo (2019)
10.1136/jitc-2020-001408
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review
Marc Lecoultre (2020)
10.1038/s41582-018-0038-3
New glioblastoma heterogeneity atlas — a shared resource
W. Wick (2018)
10.1242/dmm.034462
The metabolic axis of macrophage and immune cell polarization
Spencer A Hobson-Gutierrez (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar